Generics

The generic of Valeant's drug for chorea associated with Huntington disease had a U.S. market size of roughly $288.1 million for the 12 months ended January 2018, according to IQVIA data.

Anda hosted their 11th Annual Supply Chain Symposium, a two-day event leading into NACDS Annual Meeting, where they brought together industry leaders throughout the pharmaceutical supply chain.

Drug Store News talked to Ascend Labs executive vice president John Dillaway about how the Parsippany, N.J.-based company stands out in a crowded market, and what it has in store for the future.

Perennial readers of the healthcare industry’s tea leaves, IQVIA — née QuintilesIMS — is once again looking into what the future holds for the healthcare market. The IQVIA Institute for Human Data and Science recently released its report on where the global health market is headed in the next five years.

Drug Store News sat down with Stuart Amos to talk about FlavoRx, its start and where the company sees itself in the marketplace today and in the future.

The product had a U.S. market size of roughly $109 million for the 12 months ended February 2018, according to IQVIA data.

The company said it expects to ship the product — whose annual market size QVIA data pegs at around $17 million — in the near future.